Hims & Hers Health ( HIMS 6.30%) is coming off a fantastic year in 2024 when its share price skyrocketed 172%. The telehealth ...

A new request by Ozempic manufacturer Novo Nordisk could limit the availability of a type of GLP-1—semaglutides—to local ...

The Alliance for Pharmacy Compounding (APC), a trade organisation representing the compounding industry, has claimed that Novo Nordisk is "confusing the fact that the semaglutide molecule is ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

New findings on semaglutide and tirzepatide published in 2024 revealed that the medications may have benefits beyond lowering glucose levels and body weight. At the Cardiometabolic Health Congress ...

Whether you’ve just started taking semaglutide for weight loss or are considering other GLP-1 medications, you likely have many questions. These include the optimal dose, when to slow down or ...

With Tirzepatide now officially the FDA’s shortage list, it is more likely than not that Semaglutide is removed in the next 12 months, the analyst tells investors in a research note. Citi says ...

Citi downgraded Hims & Hers to Sell from Neutral with a $25 price target Discover outperforming stocks and invest smarter with Top Smart Score Stocks Filter, analyze, and streamline your search ...

A suspension of pantoprazole 2 mg/mL was prepared by triturating 20 40-mg tablets of pantoprazole,a mixing with sterile water for irrigationb and sodium bicarbonate,c and diluting to a final ...

Ozempic is an FDA-approved medication for treating type 2 diabetes. Its active ingredient is semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist that acts like the GLP-1 hormone ...

You don't need to leave your home to reliably get your prescription medications. Here are our top picks of the best services that deliver medicines. Mercey Livingston is a health and wellness ...